


Workshop



In Silico Clinical Trials Concepts and Adoption (drugs, devices, the industry and Regulatory)

March 5th, 14:00 – 20:00 CET

 This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 777119.



Webex Meeting link <https://medlab.webex.com/medlab/j.php?MTID=m5010d60ae86fe2177fc80d12758be801>

Agenda March 5th, 2021, 14:00 – 20:00 CET

14.00-14.10	Introduction	Dimitrios Fotiadis InSilc project Coordinator Professor of Biomedical Engineering, University of Ioannina / FORTH Head of the Unit of Medical Technology and Intelligent Information Systems Editor in Chief IEEE Journal of Biomedical and Health Informatics	Rapporteur Lorenza Petrini Associate Professor at the Department of Civil and Environmental Engineering, Laboratory of Biological Structure Mechanics (LaBS) at Politecnico di Milano
Session 1: In silico clinical trials projects		Chair Georgia Karanasiou Senior Researcher InSilc Coordination team	
14.10-14.15 Introduction of Speakers			
14.15-14.30	Presentation 1: InSilc- an In Silico platform for drug-eluting BVS design,	Georgia Karanasiou Senior Researcher InSilc Coordination team	

	development and evaluation	
14.30-14.45	Presentation 2: INSIST:- In Silico Clinical Trials for treatment of acute Ischemic Stroke	Alfons Hoekstra Full Professor Computational Science and Engineering, University of Amsterdam
14.45-15.00	Presentation 3: In Silico Trials within StriTuVad project	Francesco Pappalardo Associate Professor at the University of Catania
15.00-15.15	Presentation 4: SILICOFCM: In Silico Trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy	Nenad Filipović SILICOFCM project Coordinator Professor and the Head of Centre for Bioengineering at the Faculty of Engineering, University of Kragujevac
15.15-15.30	Presentation 5: Adoption of In Silico Trials: barriers and future perspectives	Marco Viceconti Professor of Computational Biomechanics, Department of Industrial Engineering Alma Mater Studiorum – University of Bologna Director of the Medical Technology Lab of the Rizzoli Orthopaedic Institute
15.30-16.00	Panel Discussion	
Session 2: Standardization and Regulatory framework		Chair
		Cristina Jori Medical Director Mediolanum Cardio Research S.r.l.
16.00-16.05 Introduction of Speakers		
In silico medicine		
16.05-16.20	Presentation 1: The evolution/ revolution of In Silico medicine	Elazer Edelman Director, Institute for Medical Engineering and Science, MIT Edward J. Poitras Professor in Medical Engineering and Science, Massachusetts Institute of Technology Professor of Medicine, Harvard Medical School Senior Attending Physician, Brigham and Women's Hospital
In silico companies perspective		
16.20-16.35	Presentation 1: InSilicoTrials - the crowdsourcing platform for modeling and simulation in Life sciences	Luca Emili CEO at InSilicoTrials
16.35-16.50	Presentation 2: In Silico Clinical Trials to support drug	François-Henri Boissel CEO at Novadiscovery

	development: why, how and what	
Clinical/Research perspective		
16.50-17.05	Presentation 1: Towards the adoption of In Silico medicine: the researcher point of view	Liesbet Geris Executive Director, VPH Institute University of Liège & KU Leuven Chair Research & Technology WG, Avicenna Alliance
17.05-17.20	Presentation 2: Towards the adoption of In Silico medicine: the clinical researcher point of view	Robert Byrne Director of Cardiology at the Mater Private Hospital, Dublin Chair of Cardiovascular Research at the Royal College of Surgeons
17.20-17.30	Coffee break	
Industrial perspective		
17.30-17.45	Presentation 1: Benefits and challenges for using CM&S for medical device development and clinical trials	David Flynn Research Fellow Global Technology Services CM&S Center of Excellence Boston Scientific
17.45-18.00	Presentation 2: Adoption of In Silico medicine: use and barriers of M&S in a Medical Technology Company	Markus Reiterer Dist. Scientist of Medtronic
18.00-18.15	Presentation 3: Adoption of In Silico Design Verification/Validation Testing in the Medical Device Industry	Dejan Krsmanovic Founder & President of CardioMed Technology
Regulatory perspective		
18.15-18.30	Presentation 1: Towards the adoption of In Silico medicine: challenges and opportunities for regulatory assessment	Flora Musuamba Vice Chair person at EMA MSWP Member of the EMA SAWP Expert in Pharmacometrics and Pharmacovigilance at the FAMHP Professor of Clinical Pharmacology at Universities of Lubumbashi and Namur
18.30-18.45	Presentation 2: Using Modeling and Simulation to Advance Regulatory Science in Medical Device Development and Research	Ali Kiapour Director of Biomechanics Research at the Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School Member of ASME V&V40 committee on computational modeling of medical devices
18.45-19.00	Presentation 3: Standards on In Silico methods for medical	Klaus Zeier Team Manager Health at DIN German Institute for Standardization

	devices - The devil really is in the details	Project Manager in the field of International European and German Standardization of Medical Devices
19.00-19.15	Presentation 4: Widespread In Silico medicine: pure fantasy or reality just around the corner?	Thierry Marchal Secretary General, Avicenna Alliance Program Director for Healthcare Solutions, ANSYS Member of eHealth stakeholder group to EU Commission
19.15-19.45	Panel Discussion	
19.45-20.00	Conclusions	